374 related articles for article (PubMed ID: 16842460)
1. Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease.
Hindorf U; Lindqvist M; Hildebrand H; Fagerberg U; Almer S
Aliment Pharmacol Ther; 2006 Jul; 24(2):331-42. PubMed ID: 16842460
[TBL] [Abstract][Full Text] [Related]
2. Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease.
Kwan LY; Devlin SM; Mirocha JM; Papadakis KA
Dig Liver Dis; 2008 Jun; 40(6):425-32. PubMed ID: 18304898
[TBL] [Abstract][Full Text] [Related]
3. Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients.
Gisbert JP; Niño P; Rodrigo L; Cara C; Guijarro LG
Am J Gastroenterol; 2006 Dec; 101(12):2769-76. PubMed ID: 17026564
[TBL] [Abstract][Full Text] [Related]
4. A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity.
Roblin X; Peyrin-Biroulet L; Phelip JM; Nancey S; Flourie B
Am J Gastroenterol; 2008 Dec; 103(12):3115-22. PubMed ID: 19086961
[TBL] [Abstract][Full Text] [Related]
5. Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ three-fold.
Gardiner SJ; Gearry RB; Begg EJ; Zhang M; Barclay ML
Clin Gastroenterol Hepatol; 2008 Jun; 6(6):654-60; quiz 604. PubMed ID: 18467186
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetics of thiopurine therapy in paediatric IBD patients.
De Ridder L; Van Dieren JM; Van Deventer HJ; Stokkers PC; Van der Woude JC; Van Vuuren AJ; Benninga MA; Escher JC; Hommes DW
Aliment Pharmacol Ther; 2006 Apr; 23(8):1137-41. PubMed ID: 16611274
[TBL] [Abstract][Full Text] [Related]
7. Choice of azathioprine or 6-mercaptopurine dose based on thiopurine methyltransferase (TPMT) activity to avoid myelosuppression. A prospective study.
Gisbert JP; Luna M; Maté J; González-Guijarro L; Cara C; Pajares JM
Hepatogastroenterology; 2006; 53(69):399-404. PubMed ID: 16795981
[TBL] [Abstract][Full Text] [Related]
8. Should thiopurine methyltransferase genotypes and phenotypes be measured before thiopurine therapy in patients with inflammatory bowel disease?
Fangbin Z; Xiang G; Minhu C; Liang D; Feng X; Min H; Pinjin H
Ther Drug Monit; 2012 Dec; 34(6):695-701. PubMed ID: 23149442
[TBL] [Abstract][Full Text] [Related]
9. Should azathioprine and 5-aminosalicylates be coprescribed in inflammatory bowel disease?: an audit of adverse events and outcome.
Shah JA; Edwards CM; Probert CS
Eur J Gastroenterol Hepatol; 2008 Mar; 20(3):169-73. PubMed ID: 18301295
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease.
Winter J; Walker A; Shapiro D; Gaffney D; Spooner RJ; Mills PR
Aliment Pharmacol Ther; 2004 Sep; 20(6):593-9. PubMed ID: 15352906
[TBL] [Abstract][Full Text] [Related]
11. Thiopurine methyltransferase gene polymorphisms in Chinese patients with inflammatory bowel disease.
Cao Q; Zhu Q; Shang Y; Gao M; Si J
Digestion; 2009; 79(1):58-63. PubMed ID: 19252404
[TBL] [Abstract][Full Text] [Related]
12. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease.
Ansari A; Patel N; Sanderson J; O'Donohue J; Duley JA; Florin TH
Aliment Pharmacol Ther; 2010 Mar; 31(6):640-7. PubMed ID: 20015102
[TBL] [Abstract][Full Text] [Related]
13. The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients.
Gilissen LP; Bierau J; Derijks LJ; Bos LP; Hooymans PM; van Gennip A; Stockbrügger RW; Engels LG
Aliment Pharmacol Ther; 2005 Oct; 22(7):605-11. PubMed ID: 16181300
[TBL] [Abstract][Full Text] [Related]
14. Thiopurine S-methyltransferase genotype and the use of thiopurines in paediatric inflammatory bowel disease Greek patients.
Gazouli M; Pachoula I; Panayotou I; Mantzaris G; Syriopoulou VP; Goutas N; Vlachodimitropoulos D; Anagnou NP; Roma-Giannikou E
J Clin Pharm Ther; 2010 Feb; 35(1):93-7. PubMed ID: 20175817
[TBL] [Abstract][Full Text] [Related]
15. Mercaptopurine treatment should be considered in azathioprine intolerant patients with inflammatory bowel disease.
Hindorf U; Johansson M; Eriksson A; Kvifors E; Almer SH
Aliment Pharmacol Ther; 2009 Mar; 29(6):654-61. PubMed ID: 19183142
[TBL] [Abstract][Full Text] [Related]
16. 6-tioguanine monitoring in steroid-dependent patients with inflammatory bowel diseases receiving azathioprine.
Roblin X; Serre-Debeauvais F; Phelip JM; Faucheron JL; Hardy G; Chartier A; Helluwaert F; Bessard G; Bonaz B
Aliment Pharmacol Ther; 2005 Apr; 21(7):829-39. PubMed ID: 15801918
[TBL] [Abstract][Full Text] [Related]
17. Monitoring of long-term thiopurine therapy among adults with inflammatory bowel disease.
Hindorf U; Lyrenäs E; Nilsson A; Schmiegelow K
Scand J Gastroenterol; 2004 Nov; 39(11):1105-12. PubMed ID: 15545169
[TBL] [Abstract][Full Text] [Related]
18. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine.
Sparrow MP; Hande SA; Friedman S; Lim WC; Reddy SI; Cao D; Hanauer SB
Aliment Pharmacol Ther; 2005 Sep; 22(5):441-6. PubMed ID: 16128682
[TBL] [Abstract][Full Text] [Related]
19. Adverse effects of azathioprine in the treatment of inflammatory bowel disease.
Martínez F; Nos P; Pastor M; Garrigues V; Ponce J
Rev Esp Enferm Dig; 2001 Dec; 93(12):769-78. PubMed ID: 11995359
[TBL] [Abstract][Full Text] [Related]
20. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.
Gearry RB; Barclay ML
J Gastroenterol Hepatol; 2005 Aug; 20(8):1149-57. PubMed ID: 16048561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
